TCIM
GBT

TIAA CREF Investment Management’s Global Blood Therapeutics, Inc. GBT Stock Holding History

TIAA CREF Investment Management’s Portfolio GBT Stock Details GBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$4.85M Buy
91,715
+1,563
+2% +$76.8K ﹤0.01% 1468
2018
Q4 		$3.7M Sell
90,152
-3,800
-4% -$142K ﹤0.01% 1570
2018
Q3 		$3.57M Sell
93,952
-8,477
-8% -$375K ﹤0.01% 1807
2018
Q2 		$4.63M Buy
102,429
+9,567
+10% +$436K ﹤0.01% 1651
2018
Q1 		$4.49M Buy
92,862
+2,751
+3% +$153K ﹤0.01% 1615
2017
Q4 		$3.55M Sell
90,111
-35,962
-29% -$1.34M ﹤0.01% 1819
2017
Q3 		$3.92M Sell
126,073
-128,972
-51% -$3.63M ﹤0.01% 1774
2017
Q2 		$6.97M Buy
255,045
+124,439
+95% +$3.7M ﹤0.01% 1366
2017
Q1 		$4.81M Buy
130,606
+37,672
+41% +$949K ﹤0.01% 1618
2016
Q4 		$1.34M Buy
92,934
+30,283
+48% +$532K ﹤0.01% 2387
2016
Q3 		$1.44K Buy
62,651
+17,890
+40% +$341K ﹤0.01% 2350
2016
Q2 		$743K Buy
44,761
+22,748
+103% +$459K ﹤0.01% 2671
2016
Q1 		$349K Sell
22,013
-9,402
-30% -$167K ﹤0.01% 2884
2015
Q4 		$1.02M Buy
31,415
+10,810
+52% +$468K ﹤0.01% 2569
2015
Q3 		$869K Buy
+20,605
New +$972K ﹤0.01% 2647

Other funds holding GBT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

TIAA CREF Investment Management's GBT Position: Q1 2019 in Review

TIAA CREF Investment Management increased its Global Blood Therapeutics, Inc. (GBT) stake by 1.7% in Q1 2019, buying an estimated $76.8K and bringing the position to 91,715 shares worth $4.85M. The position accounts for ﹤0.01% of the portfolio, ranked #1468.

TIAA CREF Investment Management first reported a position in GBT in Q3 2015 and has held it in 15 quarters since. The position peaked at $6.97M in Q2 2017. 201 funds tracked by Wall St. Rank hold GBT as of Q1 2019.

  • TIAA CREF Investment Management held 91,715 shares of Global Blood Therapeutics, Inc. worth $4.85M as of Q1 2019.
  • TIAA CREF Investment Management bought 1,563 Global Blood Therapeutics, Inc. shares in Q1 2019, an estimated $76.8K.
  • Global Blood Therapeutics, Inc. made up ﹤0.01% of TIAA CREF Investment Management's portfolio in Q1 2019, its #1468 holding.
  • TIAA CREF Investment Management first reported a position in Global Blood Therapeutics, Inc. in Q3 2015 and has held it in 15 quarters since.
  • TIAA CREF Investment Management's Global Blood Therapeutics, Inc. position peaked at $6.97M in Q2 2017.
  • 201 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q1 2019.

Based on TIAA CREF Investment Management's 13F filing for Q1 2019, filed 14 May 2019.